Manufacturer
JOHNSON & JOHNSON SDN BHD
Contents
Bendamustine HCl
Indication
Monotherapy in patients w/ chronic lymphocytic leukaemia; indolent B-cell non-Hodgkin's lymphomas that has progressed during or w/in 6 mth w/ rituximab or rituximab-containing regimen.
Instruction
For intravenous infusion over 30 - 60 minutes. Infusion must be administered under the supervision of a physician qualified and experienced in the use of chemotherapeutic agents.
Drug interaction
Increased toxicity w/ myelosuppresive agents. Excessive immunosuppression w/ risk of lymphoproliferation w/ cyclosporine or tacrolimus. Reduced Ab formation & increased risk of infection by cytostatics. CYP1A2 inhibitors eg, fluvoxamine, ciprofloxacin, acyclovir & cimetidine.
Malaysia
